Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201912 | 1.00 | ALDH1A1 (0.47) | ALDH1A1HDAC8FNTAFNTBATM | |
| SCHEMBL893889 | 0.84 | TRPA1 (0.40) | ALDH1A1 | |
| SCHEMBL893983 | 0.83 | TRPA1 (0.46) | ALDH1A1HDAC8 | |
| SCHEMBL893796 | 0.82 | ALDH1A1 (0.69) | ALDH1A1 | |
| SCHEMBL10203304 | 0.82 | ALDH1A1 (0.69) | ALDH1A1 | |
| SCHEMBL10203302 | 0.78 | ALDH1A1 (0.45) | ALDH1A1HDAC8FNTAFNTBATM | |
| SCHEMBL893785 | 0.78 | ALDH1A1 (0.45) | ALDH1A1HDAC8FNTAFNTBATM | |
| SCHEMBL6919707 | 0.77 | CYP3A4 (0.52) | ALDH1A1KLKB1 | |
| SCHEMBL894009 | 0.77 | TRPA1 (0.42) | HDAC8HCRTR1P2RX7 | |
| SCHEMBL30838099 | 0.76 | ALDH1A1 (0.50) | ALDH1A1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | disclosed |
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083474-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | TRPA1, TRPV1, TRPV2 | ALDH1A1 1469/4885HDAC8 288/4885FNTA 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.